Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mate, you are so obnoxious. You haven't realized that you reek. You are not a NWBO investor. You come on this board impersonating as military man, government inspector, GBM patients, CHM attendee with sole purpose to deceive the retailers. You think you are going to run away with all these nonsense? How much money have you ripped off from the NWBO shareholders? That's something we all want to find out.
Does your wife and children know what you are doing? You strike me as another Bernie Madoff.
Read your posts again to see if these posts can jog your memory.
You don't? Search ihub to see if there is anyone else who uses the word "mate" frequently.
I just need to make sure that you are the one who has the GBM.
I could be a basement dweller. But who are you? Are you that billionaire who hire all these minions to bash a company which is trying to treat cancer?
BTW, when are you going to sue me? Please do. I want so badly to have full disclosure of both of us to the world.
You attended the CHM and shared your testimony. Did I get that right?
Great.
You are rich enough to afford private doctors. You don't mind I double check with the two doctors to verify if you are telling the truth, do you?
https://kingsprivate.com/consultant/dr-istvan-bodi/
https://kingsprivate.com/consultant/mr-ranj-bhangoo/
Wow, you know a lot about this stuff. Now tell me who did the server attack on virtualtrials.org on May 10.
BTW the dark forces issue you check or pay you cash?
And you do know even in UK impersonating a government officer with the intent to deceive is considered a crime?
I am only concerned about your intent.
Senior Global Study Manager – Cell Therapy, Oncology R&D, Early Clinical
locations Gaithersburg, Maryland, United States Waltham, Massachusetts, United States South San Francisco, California, United States https://careers.astrazeneca.com/job/gaithersburg/senior-global-study-manager-cell-therapy-oncology-r-and-d-early-clinical/7684/64469951424
I would like to borrow the last two words from Perk_Idaho's post and throw at you.
Mate,
On one hand, you claim all your proceeds from NVCR will go to charity; on the other hand, you are trying to bankrupt a company that will deliver the much-needed treatment to one of the most life-threatening cancer. Do you have dissociative identity disorder? Seems like you need to worry about your own mental health. Take a look at the following statistics. How could you sleep at night?
I can give credit to what you said. But first you have to confirm that you are the one who said the following.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174095255
biosectinvestor,
I went through all the trials on cancer SWOG was running. It seems like that SWOG is playing with various combinations of the different drugs from all the BPs. I haven't seen any extraordinary results from any of these trials. I am really curious about the objectives of these trials. Is SWOG trying to find some combinations that are really working? It seems like SWOG is trying to convince people that none of these combinations are working.
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
https://classic.clinicaltrials.gov/ct2/show/NCT04071457?recrs=ab&lead=swog&draw=2&rank=26
Daratumumab -- Janssen Biotech, Inc.
Lenalidomide -- Bristol Myers Squibb
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
https://classic.clinicaltrials.gov/ct2/show/NCT04205968?recrs=ab&lead=swog&draw=2&rank=24
Paclitaxel -- Bristol-Myers Squibb
Ramucirumab -- Eli Lilly
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (PROBE)
https://classic.clinicaltrials.gov/ct2/show/NCT04510597?recrs=ab&lead=swog&draw=2&rank=21
Nivolumab -- Bristol-Myers Squibb
Pembrolizumab -- Merck
Avelumab -- Merck KGaA and Pfizer
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
https://classic.clinicaltrials.gov/ct2/show/NCT04511013?recrs=ab&lead=swog&draw=2&rank=20
Binimetinib -- Pfizer
Encorafenib -- Pfizer
Ipilimumab -- Bristol-Myers Squibb
Nivolumab -- Bristol-Myers Squibb
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT04625647?recrs=ab&lead=swog&draw=2&rank=19
Sotorasib -- Amgen
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
https://classic.clinicaltrials.gov/ct2/show/NCT04647916?recrs=ab&lead=swog&draw=2&rank=18
Sacituzumab Govitecan -- Gilead
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
https://classic.clinicaltrials.gov/ct2/show/NCT05040360?recrs=ab&lead=swog&draw=2&rank=15
Capecitabine -- Roche
Temozolomide -- Merck
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT05364645?recrs=ab&lead=swog&draw=2&rank=14
Pemetrexed -- Eli Lilly
Selpercatinib -- Eli Lilly
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
https://classic.clinicaltrials.gov/ct2/show/NCT05561387?recrs=ab&lead=swog&draw=2&rank=12
Bortezomib -- Takeda
Daratumumab and Hyaluronidase-fihj -- Johnson & Johnson
Lenalidomide -- Bristol-Myers Squibb
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
https://classic.clinicaltrials.gov/ct2/show/NCT05633602?recrs=ab&lead=swog&draw=2&rank=10
Pembrolizumab -- Merck
Ramucirumab -- Eli Lilly
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
https://classic.clinicaltrials.gov/ct2/show/NCT05633615?recrs=ab&lead=swog&draw=2&rank=9
Axicabtagene Ciloleucel -- Gilead
Lisocabtagene Maraleucel -- Bristol-Myers Squibb
Tisagenlecleucel -- Novartis
Polatuzumab Vedotin -- Roche
Mosunetuzumab -- Roche
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT05642572?recrs=ab&lead=swog&draw=2&rank=8
Capmatinib -- Novartis
Osimertinib -- AstraZeneca
Ramucirumab -- Eli Lilly
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
https://classic.clinicaltrials.gov/ct2/show/NCT05806515?recrs=ab&lead=swog&draw=2&rank=6
Carboplatin -- Bristol-Myers Squibb
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
https://classic.clinicaltrials.gov/ct2/show/NCT05890352?recrs=ab&lead=swog&draw=2&rank=5
Lenalidomide -- Bristol-Myers Squibb
Tafasitamab -- Incyte
Tazemetostat -- Ipsen
Zanubrutinib -- BeiGene
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT05929768?recrs=ab&lead=swog&draw=2&rank=4
Carboplatin -- Bristol-Myers Squibb
Paclitaxel -- Bristol-Myers Squibb
Pembrolizumab -- Merck
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06031688?recrs=ab&lead=swog&draw=2&rank=2
Ramucirumab -- Eli Lilly
Tepotinib -- Merck KGaA
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06116682?recrs=ab&lead=swog&draw=2&rank=1
Amivantamab -- Janssen and Genmab
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT04268550?recrs=bd&lead=swog&draw=2&rank=6
Selpercatinib -- Eli Lilly
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT05096663?recrs=bd&lead=swog&draw=2&rank=4
Nogapendekin Alfa -- ImmunityBio
Pembrolizumab -- Merck
Ramucirumab -- Eli Lilly
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06116682?recrs=bd&lead=swog&draw=2&rank=1
Amivantamab -- Janssen and Genmab
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06031688?recrs=bd&lead=swog&draw=2&rank=2
Ramucirumab -- Eli Lilly
Tepotinib -- Merck KGaA
So RevImmune solely owned by LP would prefer to use other DC vaccines while LP knew very well about the efficacy of DCVax-L. Do you have other smart ways to counter my point?
You are saying that they skipped any safety and dosage determination on the new DC vaccine and directly combined with CYT107. They did the same on the ATL-DC. No safety and dosage escalation evaluation and they adopted measures that were never tried before in any other trials. Are you kidding me?
I am very curious who was behind the attack on virtualtrials.org server during May 10 presentation. Seems like a lousy attack. It can be easily traced.
What do you feel about the other company owned by LP?
The company called Novamune was founded in 2018. In 2018, the colorectal trial was finished since the trial was started the beginning of 2017 and lasted only half year. Did Merck also snap away the current combo from BMS in 2018? If I am not mistaken, LP withdrew from M2GEN board in 2017 or 2018 before Merck struck partnership with Aster Insights formerly M2GEN.
https://suite.endole.co.uk/insight/company/11323970-novamune-limited
If the colorectal trial were real, then without doubt RevImmune solely owned by LP and also listed as one of the inventors of the combo patent could run some other trials as long as there were no finance issues.
Take a look at the description from the former CMO of Cytheris. BPs had close contact with Cytheris before LP acquired it.
What's your take on the combo trial of DCVax-L combined with CYT107 on three pediatric cancers? Would you agree the results are truly amazing? Don't tell me it is not DCVax-L because I am not three year ago. Have you seen me replying to the nonsense of ATL-DC is not DCVax-L you conjured up? It is so frivolous!
Ex,
You should seriously go through all the publication records that I listed about Markus Moehler. Everyone having commonsense can see that his collaboration with Merck and other BPs have been becoming intensive even since he was the PI of the colorectal trial. The founder of BioNTech used to a professor from Mainz. Why did BioNTech push their mRNA trial in such a big hurry? The trial was supposed to be initiated in 2026. They enrolled the first patient in last December.
You do realize that it is not the stuff currently in the public domain that will engulf the Wolfpack. It is the stuff currently hidden that will do the checkmate.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174356517
Did you tell your cousin what you were doing everyday?
You are talking about the poly-iclc trial again. Did I remind you another trial which only had GBM patients enrolled? Why didn't you mention the fact that there are over 60 GBM patients alive who received DCVax-L treatment? You do know there was a small trial on pediatric GBM which delivered fabulous results. You know exactly why those GBM patients from the poly-iclc trial didn't have OS over fiver years, do you not? That's exactly the reason plx3397 will be included in the new trial.
They can slash other programs which will not deliver immediate results to get the funds. Just like what BPs have been doing: abandon early development programs.
It is interesting that the award of the contract was notified on Oct 13, 2022. But Battelle chose to PR the news on January 5, 2023.
https://sam.gov/opp/7e1633cf1ec74254a0fdfb59aca9ae86/view
https://www.battelle.org/insights/newsroom/press-release-details/battelle-amplifybio-andelyn-biosciences-win-research-contract-for-national-institute-of-neurological-disorders-and-stroke
If it were not a huge issue, you and your buddies would take a break over weekends.
Do you what to know why?
It is probably the same reason that LP withdrew from the M2Gen board after being the board member for eight years before Merck started collaboration with the company.
M2Gen (now Aster insights) Announces That Merck & Co. Joins The Oncology Research Information Exchange Network (ORIEN) Avatar Research Program
https://www.biospace.com/article/releases/m2gen-announces-that-merck-and-co-joins-the-b-oncology-research-information-exchange-network-orien-b-avatar-research-program-/
Roman,
Great post!
The value is only for cancer. I put a multiplier on your number if I want to include the fields like antiviral, antibacteria, antifungus, autoimmune diseases.
You didn't see the presentation about the Moonshot in which the colorectal cancer and the brain tumor were specifically mentioned, did you?
You can laugh for now. Don't forget. I'll have the last laugh.
Truthfan,
Did you notice what Battelle was doing with the $149m fund? It was something related to small peptide, Liquid Chromatography with Tandem Mass Spectrometry, and enzyme-linked immunospot (ELISPOT) assay, which makes me have fantasy.
https://www.battelle.org/insights/newsroom/press-release-details/battelle-amplifybio-andelyn-biosciences-win-research-contract-for-national-institute-of-neurological-disorders-and-stroke
https://govtribe.com/award/federal-idv-award/indefinite-delivery-contract-75n95022d00021
How long have you been roaming on this board? 12 years?
I don't mean to brag. But holding this ticker for about three years, I know a lot better than you. I think the reason could be you are hired by someone so you have no motivation to study hard and dig deeper.
Ned,
Now you know the colorectal trial is real, don't you?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174356517
Be prepared that RevImmune most likely could have a bunch of secret trials.
Thanks for the post!
I assume you have champagne ready for the celebration!
In the PR in 2016 on the collaboration trial between Merck and NWBO, LP said the trial took more than 2 years of planning and work. The PI of the collaboration trial was Markus Moehler. I went through some of his publications between 2013 and 2023 to see if he had been in contact with Merck. I suspect if there are still some people who claimed that this trial never happened. The collaboration between Markus Moehler and Merck reminds me of the interaction between Vivek Subbiah and NWBO.
Or you can simply wait.
By now, you should be smart enough to know that Laura Posner or Elliott Leary would be able to get IP address of each poster on NWBO board.
libel? Which part is libel? Nemesis18's post style is very similar to yours, would you agree?